Clinical Trials in Denmark / NCT04851717
Active, not recruiting
Phase 2/3
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
NCT04851717 · tracked via the Priya Life Science Denmark tracker
Condition(s) studied
Pediatric ALL
Investigational drug(s) / intervention(s)
Remimazolam: Remimazolam for intravenous sedation
Study summary
To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures
Eligibility
Inclusion Criteria:
* Signed informed consent form and/or assent and willingness of patient and parent(s) to participate in the trial.
* In US sites: Paediatric male or female patients, aged ≥3 and \<18 years scheduled to undergo a diagnostic or therapeutic procedure, which is medically indicated and independent from the trial.
* In European sites: Paediatric male or female patients, aged full term birth to \<18 years scheduled to undergo a diagnostic or therapeutic procedure, which is medically indicated and independent from the trial.
* Maximum planned duration of procedure: 2 hours
* ASA Physical Status I-III
* Planned spontaneous breathing during sedation
* A female who is of child bearing potential (i.e. after menarche) and sexually active must use a highly effective method of birth control during the trial period (from the time of consent until all specified observations are completed)
* Negative pregnancy test at screening and on treatment day -
Exclusion Criteria:
* Emergency procedures
* Condition/procedure that requires planned airway control via endotracheal tube or LMA/IGEL insertion
* Cranio-facial malformation, which would severely limit the possibilities for emergency airway rescue
* Other abnormalities relating to the airway (including large tonsils and anatomical abnormalities of upper airway or lower airway) which may compromise emergency airway rescue
* Known hypersensitivity to benzodiazepines, flumazenil, dextran or any of the ingredients of the drug product
* Known paradoxical reactions to benzodiazepines
* History of sleep apnoea
* Active respiratory failure
* Active neuromuscular disease
* Active cardiac failure
* Active hepatic failure
* Breast feeding females
* Prohibited medication
* Any patient judged by the Principal Investigator (PI) or Sub-Investigator to be inappropriate for the trial for any other reason
Primary outcome measure(s)
- Success of the procedure — 2 hours
Success of the procedure defined as: Completion of the procedure AND no requirement for rescue sedative medication AND no requirement for more than the permitted bolus or infusion regimen
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| Stanford University | Palo Alto | California | |
| University of California Davis Children's Hospital | Sacramento | California | |
| Boston Children's Hospital | Boston | Massachusetts | |
| University of Minnesota Masonic Children's Hospital | Minneapolis | Minnesota | |
| University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | |
| Texas Children's Hospital | Houston | Texas | |
| Rigshospitalet | Copenhagen | Denmark | |
| Odense Universitetshospital | Odense | Denmark |
Other trials for the same condition
Nurture by Nature Feasibility Study
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04851717 on ClinicalTrials.gov ↗ ← All trials in Denmark